Skip to main content
Premium Trial:

Request an Annual Quote

Millipore Announces Date of Make-Whole Fundamental Change

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Millipore said today that with the completion of its purchase by Merck KGaA, it is delivering a notice to holders of its 3.75 percent Convertible Senior Notes due 2026 that the effective date of the Make-Whole Fundamental Change was July 14, when the deal was completed.

The purchase's completion also triggered an increase in the conversion rate "applicable to notes surrendered for conversion during the Make-Whole Conversion period," Millipore said.

As a result of the Make-Whole Fundamental Change, the conversion rates applicable to notes surrendered for conversion during the Make-Whole Convertibility period is being increased to 0.7519 shares per $1,000 principal amount of notes, resulting in an additional cash payment of $80.46 for each $1,000 in principal amount of notes.

Holders of such notes must surrender them during the Make-Whole Conversion period, which began on June 14 and ends the latter of Aug. 25 and the "Fundamental Change Repurchase Date, which Millipore will announce within 20 business days after consummation of the share exchange.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.